DDX17 and hepatocellular carcinoma: Nevertheless, the oncogenic role of DDX17 as a transcriptional co-activator in HCC remains incompletely understood, and studies were urgently needed to systematically investigate the underlying molecular mechanism in DDX17-mediated HCC progression both in vitro and in vivo.